PCRX vs WST
PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain. WST: West Pharmaceutical Services provides essential high-quality, sterile packaging and delivery systems for injectable medications globally.
Side-by-side fundamentals
| Metric | PCRX | WST | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $26.97 | $331.25 | |
| Market cap as of 2026-07-31 | $1.1B | $23.3B | |
| P/E as of 2026-07-31 | 215.76 | 42.91 | WST lower |
| PEG as of 2026-07-31 | 17.75 | 3.24 | WST lower |
| Net margin as of 2026-07-31 | +0.7% | +17.0% | WST higher |
| Gross margin as of 2026-07-31 | +79.3% | +36.8% | PCRX higher |
| Operating margin as of 2026-07-31 | +0.1% | +20.4% | WST higher |
| ROE as of 2026-07-31 | +0.7% | +18.5% | WST higher |
| ROA as of 2026-07-31 | +0.4% | +13.6% | WST higher |
| Debt / equity as of 2026-07-31 | 0.56 | 0.07 | WST lower |
| Revenue growth (YoY) as of 2026-07-31 | +4.6% | +12.4% | WST higher |
| Revenue CAGR (3y) SEC XBRL | +2.9% | +2.1% | PCRX higher |
| Dividend yield as of 2026-07-31 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-31 | 0.32 | 1.13 | |
| 1-year return as of 2026-07-30 close | +23.9% | +25.7% | WST higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.